AUS
NZ
UK
CA
USA
IND
Highlights
- Short interest in Fresenius Medical Care decreased by 5.1% in December.
- Hedge funds, including Wulff Hansen & Co., significantly raised their stakes in FMS.
- The stock’s performance continues to show stability with a 50-day.
Fresenius Medical Care has experienced a 5.1% decline in short interest as of December, signaling a shift in market dynamics. The company's stock shows resilience, with several institutional investors increasing their stakes. This movement aligns with broader trends in the NYSE Healthcare Stocks sector, where performance and investor activity are key drivers of stock behavior.
Short Interest Decline in Fresenius Medical Care (NYSE:FMS)
Fresenius Medical Care saw a significant reduction in short interest during December, decreasing by 5.1%. As of December 15th, short interest totaled 808,800 shares, compared to 852,500 shares on November 30th. With an average daily trading volume of 272,600 shares, this brings the days-to-cover ratio to 3.0, indicating how long it would take for all short positions to be covered based on current trading volumes.
Stock Performance of Fresenius Medical Care
FMS stock opened at $22.71 on Tuesday, showing resilience in the market. The company boasts a market capitalization of $13.33 billion and a price-to-earnings ratio of 18.77. The stock has experienced modest price movements, with a 50-day simple moving average of $22.13 and a 200-day average of $20.60. Over the last year, the stock has fluctuated between a low of $17.93 and a high of $24.31, reflecting moderate volatility.
In terms of liquidity and financial health, Fresenius Medical Care maintains a current ratio of 1.37 and a quick ratio of 1.02. These metrics highlight the company’s ability to meet short-term obligations. Additionally, its debt-to-equity ratio stands at a manageable 0.42, indicating a stable financial structure.
Institutional Activity and Stake Changes
Several hedge funds and institutional investors have adjusted their positions in Fresenius Medical Care. Wulff Hansen & Co. made a significant increase in their stake by 1,809%, acquiring an additional 325,439 shares during the second quarter. Similarly, Moran Wealth Management LLC and Quantinno Capital Management LP raised their stakes in the company by 47.0% and 78.9%, respectively, during the third quarter.
Crossmark Global Holdings Inc. also boosted its position by 60.4%, while Connor Clark & Lunn Investment Management Ltd. entered a new position in the third quarter. Overall, institutional investors hold 8.37% of the stock, which adds to the company’s stability and investor confidence.
Fresenius Medical Care Services
Fresenius Medical Care provides essential dialysis and related services for individuals with renal diseases, both in Germany and internationally. The company operates a network of outpatient dialysis clinics and offers comprehensive patient care, including clinical monitoring, follow-up assistance, and supply delivery. In the U.S., the company also offers dialysis services to hospitals for end-stage renal disease (ESRD) patients and those suffering from acute kidney failure. These services play a vital role in supporting patients with chronic conditions, contributing to the company’s continued relevance in the healthcare sector.
